




5804/4624

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 800




**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

A. S. S. S. S.

Dated 17 December 2004

THE PATENT OFFICE

F

04 NOV 2003

NEWPORT



04NOV03 E849202-1 C82885
P01/7700 0.00-0325655.9

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

MNL7

2. Patent application number

(The Patent Office will fill this part in)

0325655.9

04 NOV 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

MOLECULAR NATURE LIMITED

12 CRAUFURD RISE

MAIDENHEAD

BERKSHIRE

SL6 7LS

UK

8337255001

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

ANTIBACTERIAL COMPOSITIONS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

DR. VINCENT A. PRICE

PRICE & CO.

CARR HOUSE

KIRKLEES HALL

CLIFTON

WEST YORKSHIRE

HD6 4HD

8337248001

Patents ADP number (if you know it)

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

YES

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description 19 —

Claim(s) 9 —

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)


Request for a preliminary examination and search (Patents Form 9/77)

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)



Date 30/10/03

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

DR. V. A. PRICE

01484 710970

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

ANTIBACTERIAL COMPOSITIONS

Field of the Invention

- 5 The present invention relates to (alkyl)aminopyrrolizidine compounds and to their use in medicine. In particular, the invention relates to the use of (alkyl)aminopyrrolizidine compounds as antibacterial drugs.

Background to the Invention

- 10 Many bacterial infections are presently effectively treated with antibiotics and prevented with various vaccines. However, bacterial infections still cause large numbers of fatalities. In particular, the rise in the incidence of multi-drug resistant bacterial infections has made the need for alternative means of treatment more pressing, while the
15 use of anthrax spores as a biological weapon has focused attention on the need for widely available and effective antimicrobial agents effective against *Bacillus anthracis*.

- The number of nosocomial infections due to antibiotic resistant bacteria has increased sharply in recent years. Methicillin-resistant *Staphylococcus aureus* (MRSA) has emerged
20 as one of the main causative agents. MRSA infections are presently treated with the glycopeptide antibiotic vancomycin. However, there are indications that the continued use of vancomycin to treat MRSA infections could give rise to a fully glycopeptide resistant population of *Staphylococcus aureus*. Thus, there is a need for further antimicrobial agents for the treatment of antibiotic resistant bacterial infections.

- 25 Anthrax is caused by the bacterium *Bacillus anthracis*. While anthrax commonly affects hoofed animals such as sheep and goats, humans may also acquire this disease. Historically, the principal risk factor for inhalation anthrax is the inhalation of anthrax spores from industrial processes such hide tanning and wool processing. However,
30 anthrax has recently been used as a biological weapon in bio-terrorism.

- There are usually two stages of inhalation anthrax. The first stage can last from hours to a few days and is similar to a flu-like illness with fever, headache, cough, shortness of breath, and chest pain. The second stage often develops suddenly and is characterized by
35 shortness of breath, fever, and shock. The prognosis of inhalation anthrax once it reaches the second stage is poor, even with antibiotic therapy and up to 90% of cases in the second stage are fatal.


There is therefore a need for further antimicrobial agents effective in the treatment of anthrax.

5

Summary of the Invention

According to a first aspect of the invention there is provided an antibacterial (alkyl)aminopyrrolizidine compound, which compound is: (a) for use in therapy or prophylaxis, and/or (b) in a pharmaceutical composition, and/or (c) in a unit dosage form, and/or (d) in a form suitable for local or systemic administration.

The compound may be a pharmaceutically acceptable derivative of loline:




15

Loline is a naturally-occurring alkaloid found, for example, in certain grasses.

Preferably, the compound has a saturated or unsaturated (alkyl)aminopyrrolizidine nucleus of formula:

20




Alternatively, the compound may have a saturated or unsaturated (alkyl)aminopyrrolizidine nucleus of formula:

25



In preferred embodiments, the compounds are hydroxylated. Particularly preferred are compounds which are mono- or dihydroxylated.

In a second aspect the invention provides a compound having the formula:



5

in which a, b, c, d, e and f indicate the location of optional C=C double bonds, provided, however, that the double bonds are not adjacent and that when one or more double bond(s) are present then the substitution patterns around such bonds do not violate double bond valency, wherein R¹ is amino or alkyl amino, R² and R³ are independently selected from hydrogen, oxo, halo, hydroxy and alkoxy and wherein the compound is:

- (a) for use in therapy or prophylaxis; and/or
- (a) in isolated or purified form; and/or
- 15 (b) in a pharmaceutical composition; and/or
- (c) in a unit dosage form; and/or
- (d) in a form suitable for local or systemic administration,

20

or a pharmaceutically acceptable salt or derivative thereof.

The alkyl amino is preferably C₁-C₁₀ alkyl amino (for example, C₁-C₆ alkyl amino, e.g. C₁-C₄ alkyl amino). The alkoxy is preferably C₁-C₁₀ alkoxy (for example, C₁-C₆ alkoxy, e.g. C₁-C₄ alkoxy).

- 25 The alkyl amino may be a C₁, C₂, C₃, C₄, C₅ or C₆ alkyl amino, while the alkoxy may be a C₁, C₂, C₃, C₄, C₅ or C₆ alkoxy. The halo may be chloro, fluoro, iodo or bromo, preferably chloro, fluoro or iodo.

The compounds contemplated according to the second aspect of the invention may be saturated or unsaturated.


30

Preferred unsaturated compounds of the invention are 1,2-dehydro-, 5,6-dehydro-, 6,7-dehydro or 7,8-dehydro.


Preferred are compounds in which R^2 and/or R^3 are hydroxy and/or wherein R^1 is amino or C_1 alkyl amino (methylamino).

Particularly preferred are compounds selected from:


(a) 2,7-dihydroxy-1-methylaminopyrrolizidine:




(b) 2,7-dihydroxy-1-aminopyrrolizidine:




(c) 2-hydroxy-1-aminopyrrolizidine:




(d) 2-hydroxy-1-methylaminopyrrolizidine:



(e) 7-hydroxy-1-aminopyrrolizidine:




(f) 7-hydroxy-1-methylaminopyrrolizidine:




5

(g) 1 α -methylamino-2 β -hydroxypyrrolizidine:



10


(h) 1 α -methylamino-7 β -hydroxypyrrolizidine:



15

- (i) 1 α -amino-2 β -hydroxypyrrolizidine;
- (j) 1 α -amino-7 β -hydroxypyrrolizidine;
- (k) 1 α -amino-2,7 β -hydroxypyrrolizidine;
- (l) 1 α -methylamino-2,7 β -hydroxypyrrolizidine.

20 Also preferred are compounds wherein R¹ is C₁ alkyl amino (methylamino) and R² and R³ are oxo. Such compounds have the formula:



Other preferred compounds are saturated wherein R¹, R² and R³ are as shown below:

R ¹	R ²	R ³
Amino	Hydrogen	Hydrogen
Amino	Hydrogen	Oxo
Amino	Hydrogen	Hydroxy
Amino	Hydrogen	Halo
Amino	Hydrogen	Alkoxy
Amino	Oxo	Hydrogen
Amino	Oxo	Oxo
Amino	Oxo	Hydroxy
Amino	Oxo	Halo
Amino	Oxo	Alkoxy
Amino	Hydroxy	Hydrogen
Amino	Hydroxy	Oxo
Amino	Hydroxy	Hydroxy
Amino	Hydroxy	Halo
Amino	Hydroxy	Alkoxy
Amino	Halo	Hydrogen
Amino	Halo	Oxo
Amino	Halo	Hydroxy
Amino	Halo	Halo
Amino	Halo	Alkoxy
Amino	Alkoxy	Hydrogen
Amino	Alkoxy	Oxo
Amino	Alkoxy	Hydroxy
Amino	Alkoxy	Halo
Amino	Alkoxy	Alkoxy
Methylamino	Hydrogen	Hydrogen
Methylamino	Hydrogen	Oxo
Methylamino	Hydrogen	Hydroxy
Methylamino	Hydrogen	Halo
Methylamino	Hydrogen	Alkoxy
Methylamino	Oxo	Hydrogen
Methylamino	Oxo	Oxo

Methylamino	Oxo	Hydroxy
Methylamino	Oxo	Halo
Methylamino	Oxo	Alkoxy
Methylamino	Hydroxy	Hydrogen
Methylamino	Hydroxy	Oxo
Methylamino	Hydroxy	Hydroxy
Methylamino	Hydroxy	Halo
Methylamino	Hydroxy	Alkoxy
Methylamino	Halo	Hydrogen
Methylamino	Halo	Oxo
Methylamino	Halo	Hydroxy
Methylamino	Halo	Halo
Methylamino	Halo	Alkoxy
Methylamino	Alkoxy	Hydrogen
Methylamino	Alkoxy	Oxo
Methylamino	Alkoxy	Hydroxy
Methylamino	Alkoxy	Halo
Methylamino	Alkoxy	Alkoxy
Alkylamino	Hydrogen	Hydrogen
Alkylamino	Hydrogen	Oxo
Alkylamino	Hydrogen	Hydroxy
Alkylamino	Hydrogen	Halo
Alkylamino	Hydrogen	Alkoxy
Alkylamino	Oxo	Hydrogen
Alkylamino	Oxo	Oxo
Alkylamino	Oxo	Hydroxy
Alkylamino	Oxo	Halo
Alkylamino	Oxo	Alkoxy
Alkylamino	Hydroxy	Hydrogen
Alkylamino	Hydroxy	Oxo
Alkylamino	Hydroxy	Hydroxy
Alkylamino	Hydroxy	Halo
Alkylamino	Hydroxy	Alkoxy
Alkylamino	Halo	Hydrogen
Alkylamino	Halo	Oxo

Alkylamino	Halo	Hydroxy
Alkylamino	Halo	Halo
Alkylamino	Halo	Alkoxy
Alkylamino	Alkoxy	Hydrogen
Alkylamino	Alkoxy	Oxo
Alkylamino	Alkoxy	Hydroxy
Alkylamino	Alkoxy	Halo
Alkylamino	Alkoxy	Alkoxy

Unsaturated compounds according to the invention may also have R¹, R² and R³ as shown in the table above. Such compounds may, for example, be 1,2-dehydro-, 5,6-dehydro-, 6,7-dehydro or 7,8-dehydro.

In the compounds listed in the table above, the alkoxy is preferably C₁, C₂, C₃, C₄, C₅ or C₆ alkoxy, the alkylamino is preferably C₁, C₂, C₃, C₄, C₅ or C₆ alkylamino and the halo is preferably chloro, fluoro, iodo or bromo.

In another aspect, the invention provides a method of treating a bacterial infection comprising administering the compound of the invention to a patient.

Any bacterial infection may be treated using the compounds of the invention, but preferred are bacterial infections with a Gram-positive bacteria (especially low G+C Gram-positive bacteria, including *Staphylococcus* spp. or *Bacillus* spp.)

The invention finds particular utility in the treatment of infection with *S. aureus* or *S. epidermidis*.

The compounds of the invention may also be used to treat infection with MRSA, for example selected from any of C-MRSA1, C-MRSA2, C-MRSA3, C-MRSA4, Belgian MRSA, Swiss MRSA and any of the EMRSA strains. Accordingly, the invention therefore finds utility in the treatment or prophylaxis of infections mediated by drug-resistant bacteria and in the treatment or prophylaxis of nosocomial infections.

In yet other applications, the compounds of the invention are used to treat infection with *Bacillus anthracis*, and the invention therefore finds utility in the treatment or prophylaxis of anthrax.

- 5 In another aspect, the invention contemplates the use of the compounds of the invention for the manufacture of a medicament for use as an antibacterial agent.

In yet another aspect, the invention provides a process for the manufacture of an antibacterial agent characterized in the use of the compound of the invention.

10

In another aspect, the invention contemplates a composition comprising the compound of the invention in combination with:

- 15 (a) an antimicrobial (e.g. antibacterial) agent; and/or
(b) an antiviral agent; and/or
(c) an anti-inflammatory; and/or
(d) an analgesic; and/or
(e) an immunostimulant.

- 20 Such compositions find particular utility in adjunctive therapies.

The invention also contemplates a pharmaceutical kits of parts comprising the compound of the invention, optionally in combination with an adjunctive therapeutic agent (for example those listed as (a) to (e), above). Such kits may further comprise instructions for
25 use in antibacterial treatment or prophylaxis.

- 30 In another embodiment, the invention covers wound dressings, surgical implants, disinfectant scrubs, wipes and other surgical equipment or lotions comprising the compound of the invention. The compound of the invention may also find application in methods for cleaning and/or sterilizing medical instruments, in pre-operative surgical scrubs and in operating theatre hygiene maintenance procedures.

Detailed Description of the Invention

Definitions

- 5 Where used herein and unless specifically indicated otherwise, the following terms are intended to have the following meanings in addition to any broader (or narrower) meanings the terms might enjoy in the art:

10 A *pharmaceutical composition* is a solid or liquid composition in a form, concentration and level of purity suitable for administration to a patient (e.g. a human or animal patient) upon which administration it can elicit the desired physiological changes. Preferably, the pharmaceutical compositions of the invention comprise the compound of the invention together with a pharmaceutical excipient.

- 15 The term *isolated* as applied to the compounds of the invention is used herein to indicate that the compound exists in a physical milieu distinct from that in which it occurs in nature. For example, the isolated material may be substantially isolated (for example purified) with respect to the complex cellular milieu in which it naturally occurs. When the isolated material is purified, the absolute level of purity is not critical and those skilled
20 in the art can readily determine appropriate levels of purity according to the use to which the material is to be put. Preferred, however, are purity levels of 90% w/w, 99% w/w or higher. In some circumstances, the isolated compound forms part of a composition (for example a more or less crude extract containing many other substances) or buffer system, which may for example contain other components. In other circumstances, the isolated
25 compound may be purified to essential homogeneity, for example as determined spectrophotometrically, by NMR or by chromatography (for example GC-MS).

- The term *pharmaceutically acceptable derivative* as applied to the compounds of the invention define compounds which are obtained (or obtainable) by chemical
30 derivatization of the parent compounds of the invention. The pharmaceutically acceptable derivatives are therefore suitable for administration to or use in contact with the tissues of humans without undue toxicity, irritation or allergic response (i.e. commensurate with a reasonable benefit/risk ratio).

- 35 Preferred derivatives are those obtained (or obtainable) by alkylation, esterification or acylation of the parent pyrrolizidine compounds of the invention. The derivatives may be

antibacterial *per se*, or may be inactive until processed *in vivo*. In the latter case, the derivatives of the invention act as prodrugs.

Pharmaceutically acceptable derivatives include all prodrugs (see below). Particularly preferred prodrugs are ester derivatives which are esterified at one or more of the free hydroxyls and which are activated by hydrolysis *in vivo*. The pharmaceutically acceptable derivatives of the invention retain some or all of the antibacterial activity of the parent compound. In some cases, the antibacterial activity is increased by derivatization. Derivatization may also augment other biological activities of the compound, for example bioavailability. The term is to be understood *mutatis mutandis* when applied to loline.

As used herein, the term *prodrug* is intended to define any covalently bonded carriers which release the antibacterial compounds of the invention *in vivo* when the prodrug is administered. Prodrugs may be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation *ex vivo* prior to administration or *in vivo*, to the antibacterial compound of the invention. Prodrugs therefore include compounds of the invention wherein a hydroxy or amino group is bonded to any group that, when the prodrug is administered, cleaves to form a free hydroxyl or free amino group, respectively. Thus, examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the invention.

The term *pharmaceutically acceptable salt* as applied to the compounds of the invention defines any non-toxic organic or inorganic acid addition salt of the free base compounds which are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and which are commensurate with a reasonable benefit/risk ratio. Suitable pharmaceutically acceptable salts are well known in the art. Examples are the salts with inorganic acids (for example hydrochloric, hydrobromic, sulphuric and phosphoric acids), organic carboxylic acids (for example acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, dihydroxymaleic, benzoic, phenylacetic, 4-aminobenzoic, 4-hydroxybenzoic, anthranilic, cinnamic, salicylic, 2-phenoxybenzoic, 2-acetoxybenzoic and mandelic acid) and organic sulfonic acids (for example methanesulfonic acid and p-toluenesulfonic acid). The drugs of the invention may also be converted into salts by reaction with an alkali metal halide, for example sodium chloride, sodium iodide or lithium iodide. Preferably, the compounds of the invention are

converted into their salts by reaction with a stoichiometric amount of sodium chloride in the presence of a solvent such as acetone.

5 These salts and the free base compounds can exist in either a hydrated or a substantially anhydrous form. Crystalline forms of the compounds of the invention are also contemplated and in general the acid addition salts of the compounds of the invention are crystalline materials which are soluble in water and various hydrophilic organic solvents and which in comparison to their free base forms, demonstrate higher melting points and an increased solubility.

10

In its broadest aspect, the present invention contemplates all optical isomers, racemic forms and diastereomers of the compounds of the invention. Those skilled in the art will appreciate that, owing to the asymmetrically substituted carbon atoms that may be present in the compounds of the invention, the compounds of the invention may exist and be
15 synthesised and/or isolated in optically active and racemic forms. Thus, references to the compounds of the present invention encompass the compounds as a mixture of diastereomers, as individual diastereomers, as a mixture of enantiomers as well as in the form of individual enantiomers.

20 Therefore, the present invention contemplates all optical isomers and racemic forms thereof of the compounds of the invention, and unless indicated otherwise (e.g. by use of dash-wedge structural formulae) the compounds shown herein are intended to encompass all possible optical isomers of the compounds so depicted. In cases where the stereochemical form of the compound is important for pharmaceutical utility, the
25 invention contemplates use of an isolated eutomer.

The term *antibacterial* is used hereinto define a compound that is capable of destroying bacteria or inhibiting or preventing bacterial growth or metabolism. Those skilled in the art will be aware of many different tests for detecting and/or quantifying antibacterial
30 activity, including for example cup plate or paper disc bioassays based on the detection/measurement of zones of inhibition in seeded agar plates.

The term *adjunctive* (as applied to the use of the compounds of the invention in therapy) defines uses in which the compound is administered together with one or more other
35 drugs, interventions, regimens or treatments (such as surgery and/or irradiation). Such adjunctive therapies may comprise the concurrent, separate or sequential administration/application of the compound of the invention and the other treatment(s).

Thus, in some embodiments, adjunctive use of the compound of the invention is reflected in the formulation of the pharmaceutical compositions of the invention. For example, adjunctive use may be reflected in a specific unit dosage, or in formulations in which the compound of the invention is present in admixture with the other drug(s) with which it is to be used adjunctively (or else physically associated with the other drug(s) within a single unit dose). In other embodiments, adjunctive use of the compound of the invention may be reflected in the composition of the pharmaceutical kits of the invention, wherein the compound of the invention is co-packaged (e.g. as part of an array of unit doses) with the other drug(s) with which it is to be used adjunctively. In yet other embodiments, adjunctive use of the compound of the invention may be reflected in the content of the information and/or instructions co-packaged with the compound relating to formulation and/or posology.

The term *surgical material* is used herein to define all materials (including equipment, compositions, tools, clothing, dressings, containers, disposables, reagents, accessories, implants and prosthetics) used in surgical operations.

The term *Gram-positive bacterium* is a term of art defining a particular class of bacteria that are grouped together on the basis of certain cell wall staining characteristics.

The term *low G+C Gram-positive bacterium* is a term of art defining a particular subclass class of evolutionarily related bacteria within the Gram-positives on the basis of the composition of the bases in the DNA. The subclass includes *Streptococcus* spp., *Staphylococcus* spp., *Listeria* spp., *Bacillus* spp., *Clostridium* spp. and *Lactobacillus* spp.).

Medical applications

The invention finds application in medicine, for example in methods of therapy and prophylaxis.

The medical applications may be applied to any warm-blooded animal, including humans. The applications include veterinary applications, wherein the compounds of the invention are administered to non-human animals, including primates, dogs, cats, horses, cattle and sheep.

The compounds of the invention are antibacterial agents. Thus, the compounds of the invention find general application as antibacterial agents. They may therefore be used in the treatment or prophylaxis or diagnosis of any bacterial infection.

5

Posology

The compounds of the present invention can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway
10 (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.

The amount of the compound administered can vary widely according to the particular dosage unit employed, the period of treatment, the age and sex of the patient treated, the nature and extent of the disorder treated, and the particular compound selected.

15

Moreover, the compounds of the invention can be used in conjunction with other agents known to be useful in the treatment of bacterial diseases, disorders or infections and in such embodiments the dose may be adjusted accordingly.

20 In general, the effective amount of the compound administered will generally range from about 0.01 mg/kg to 500 mg/kg daily. A unit dosage may contain from 0.05 to 500 mg of the compound, and can be taken one or more times per day. The compound can be administered with a pharmaceutical carrier using conventional dosage unit forms either orally, parenterally, or topically, as described below.

25

The preferred route of administration is oral administration. In general a suitable dose will be in the range of 0.01 to 500 mg per kilogram body weight of the recipient per day, preferably in the range of 0.1 to 50 mg per kilogram body weight per day and most preferably in the range 1 to 5 mg per kilogram body weight per day.

30

The desired dose is preferably presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 0.001 to 100 mg, preferably 0.01 to 10 mg, and most preferably 0.5 to 1.0 mg of active ingredient per unit dosage
35 form.

Formulation

The compositions of the invention comprise the compound of the invention, optionally together with a pharmaceutically acceptable excipient.

5

The compound of the invention may take any form. It may be synthetic, purified or isolated from natural sources.

10

When purified from a natural source, the compound of the invention may be isolated or merely purified.

15

In embodiments where the compound of the invention is formulated together with a pharmaceutically acceptable excipient, any suitable excipient may be used, including for example inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc.

20

The pharmaceutical compositions may take any suitable form, and include for example tablets, elixirs, capsules, solutions, suspensions, powders, granules and aerosols.

25

The pharmaceutical composition may take the form of a kit of parts, which kit may comprise the composition of the invention together with instructions for use and/or a plurality of different components in unit dosage form.

30

Tablets for oral use may include the compound of the invention mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

35

Capsules for oral use include hard gelatin capsules in which the compound of the invention is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

- 5 Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active
10 ingredient such carriers as are known in the art to be appropriate.

For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity.

15

Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include
20 ethyl and n-propyl p-hydroxybenzoate.

The compounds of the invention may also be presented as liposome formulations.

For oral administration the compound of the invention can be formulated into solid or
25 liquid preparations such as capsules, pills, tablets, troches, lozenges, melts, powders, granules, solutions, suspensions, dispersions or emulsions (which solutions, suspensions dispersions or emulsions may be aqueous or non-aqueous). The solid unit dosage forms can be a capsule which can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose,
30 calcium phosphate, and cornstarch.

In another embodiment, the compounds of the invention are tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch, or gelatin, disintegrating agents intended to assist the break-up and
35 dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, lubricants intended to improve the flow of tablet granulations and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches,

for example, talc, stearic acid, or magnesium, calcium, or zinc stearate, dyes, coloring agents, and flavoring agents intended to enhance the aesthetic qualities of the tablets and make them more acceptable to the patient.

5 Suitable excipients for use in oral liquid dosage forms include diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent or emulsifying agent.

10 The compounds of the invention may also be administered parenterally, that is, subcutaneously, intravenously, intramuscularly, or interperitoneally.

In such embodiments, the compound is provided as injectable doses in a physiologically acceptable diluent together with a pharmaceutical carrier (which can be a sterile liquid or
15 mixture of liquids). Suitable liquids include water, saline, aqueous dextrose and related sugar solutions, an alcohol (such as ethanol, isopropanol, or hexadecyl alcohol), glycols (such as propylene glycol or polyethylene glycol), glycerol ketals (such as 2,2-dimethyl-1,3-dioxolane-4-methanol), ethers (such as poly(ethylene-glycol) 400), an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the
20 addition of a pharmaceutically acceptable surfactant (such as a soap or a detergent), suspending agent (such as pectin, carhomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose), or emulsifying agent and other pharmaceutically adjuvants. Suitable oils which can be used in the parenteral formulations of this invention are those of petroleum, animal, vegetable, or synthetic
25 origin, for example, peanut oil, soybean oil, sesame oil, cottonseed oil, corn oil, olive oil, petrolatum, and mineral oil.

Suitable fatty acids include oleic acid, stearic acid, and isostearic acid. Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate.

30

Suitable soaps include fatty alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example, dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamines acetates; anionic detergents, for example, alkyl, aryl, and olefin sulphonates, alkyl, olefin, ether, and monoglyceride
35 sulphates, and sulphosuccinates; nonionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers; and amphoteric

detergents, for example, alkyl-beta-aminopropionates, and 2-alkylimidazoline quarternary ammonium salts, as well as mixtures.

5 The parenteral compositions of this invention will typically contain from about 0.5 to about 25% by weight of the compound of the invention in solution. Preservatives and buffers may also be used. In order to minimize or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5 to about 15% by weight. The surfactant can be a single
10 component having the above HLB or can be a mixture of two or more components having the desired HLB. Illustrative of surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.

15 The compounds of the invention may also be administered topically, and when done so the carrier may suitably comprise a solution, ointment or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.
20 Topical formulations may contain a concentration of the pyrrolizidine compound or its pharmaceutical salt from about 0.1 to about 10% w/v (weight per unit volume).

When used adjunctively, the compounds of the invention may be formulated for use with one or more other drug(s). In particular, the compounds of the invention may be used in
25 combination with an antimicrobial (e.g. antibacterial) agent, antiviral agent, anti-inflammatory, analgesic (e.g. opioids or NSAIDs) or immunostimulant.

Thus, adjunctive use may be reflected in a specific unit dosage designed to be compatible (or to synergize) with the other drug(s), or in formulations in which the compound is
30 admixed with one or more of the antimicrobial (e.g. antibacterial) agents, antiviral agents, anti-inflammatories, analgesics or immunostimulants (or else physically associated with the other drug(s) within a single unit dose). Adjunctive uses may also be reflected in the composition of the pharmaceutical kits of the invention, in which the compound of the invention is co-packaged (e.g. as part of an array of unit doses) with the antimicrobial
35 (e.g. antibacterial) agent, antiviral agent, anti-inflammatory, analgesic or immunostimulant. Adjunctive use may also be reflected in information and/or

instructions relating to the co-administration of the compound with antimicrobial agents and/or antiinflammatories.

Exemplification

5

The invention will now be described with reference to specific Examples. These are merely exemplary and for illustrative purposes only: they are not intended to be limiting in any way to the scope of the monopoly claimed or to the invention described.

10

Example 1

15

A semi-synthetic reaction mixture derived from loline was tested for activity by incubation for 12-24 hours at 37°C at various concentrations with a suspension of 1×10^3 c.f.u. of *Bacillus anthracis* SN1. After incubation, test samples were plated onto solid agar plates and colonies counted after incubation at 37°C for 24 hrs. Complete bacterial killing was observed.

Example 2

20

A semi-synthetic reaction mixture derived from loline was tested for activity by incubation for 12-24 hours at 37°C at various concentrations with a suspension of 1×10^3 c.f.u. of *Staphylococcus aureus*. After incubation, test samples were plated onto solid agar plates and colonies counted after incubation at 37°C for 24 hrs. Complete bacterial killing was observed.

25


Equivalents

30

The foregoing description detail presently preferred embodiments of the present invention. Numerous modifications and variations in practice thereof are expected to occur to those skilled in the art upon consideration of these descriptions. Those modifications and variations are intended to be encompassed within the claims appended hereto.

CLAIMS:


1. An antibacterial aminopyrrolizidine or alkylaminopyrrolizidine compound which is:
 - (a) for use in therapy or prophylaxis; and/or
 - (b) in a pharmaceutical composition; and/or
 - (c) in a unit dosage form; and/or
 - (d) in a form suitable for local or systemic administration.
2. The compound of claim 1 which is a pharmaceutically acceptable derivative of loline.
3. The compound of claim 1 or claim 2 having a saturated or unsaturated (e.g. 6,7-dehydro) aminopyrrolizidine or alkylaminopyrrolizidine nucleus of formula:



4. The compound of claim 1 or claim 2 having a saturated or unsaturated (e.g. 6,7-dehydro) aminopyrrolizidine or alkylaminopyrrolizidine nucleus of formula:



5. The compound of any one of claims 1 to 3 which is hydroxylated, for example being mono- or dihydroxylated (e.g. at C-2 and/or C-7).
6. The compound of any one of claims 1, 2 and 4 which is hydroxylated, for example being mono- or dihydroxylated (e.g. at C-1 and/or C-7).
7. A compound having the formula:



5 in which a, b, c, d, e and f indicate the location of optional C=C double bonds, provided, however, that the double bonds are not adjacent and that when one or more double bond(s) are present then the substitution patterns around such bonds do not violate double bond valency, wherein R¹ is amino or alkyl amino, R² and R³ are independently selected from hydrogen, oxo, halo, hydroxy and alkoxy and wherein the compound is:

10

- (a) for use in therapy or prophylaxis; and/or
- (b) in isolated or purified form; and/or
- (c) in a pharmaceutical composition; and/or
- (d) in a unit dosage form; and/or
- 15 (e) in a form suitable for local or systemic administration,

or a pharmaceutically acceptable salt or derivative thereof.

20

8. The compound of claim 7 wherein the alkyl amino is C₁-C₁₀ alkyl amino (for example, C₁-C₆ alkyl amino, e.g. C₁-C₄ alkyl amino) and/or the alkoxy is C₁-C₁₀ alkoxy (for example, C₁-C₆ alkoxy, e.g. C₁-C₄ alkoxy).

9. The compound of claim 8 wherein the alkyl amino is a C₁, C₂, C₃, C₄, C₅ or C₆ alkyl amino.

25

10. The compound of any one of claims 7 to 9 wherein the alkoxy is a C₁, C₂, C₃, C₄, C₅ or C₆ alkoxy.

30

11. The compound of any one of claims 7 to 10 wherein the halo is chloro, fluoro, iodo or bromo.

12. The compound of any one of the preceding claims which is saturated.

13. The compound of any one of the preceding claims which is unsaturated.

14. The compound of claim 13 which is 1,2-dehydro-, 5,6-dehydro-, 6,7-dehydro or 7,8-
5 dehydro.


15. The compound of claim 7 wherein R^2 and/or R^3 are hydroxy.

16. The compound of claim 15 wherein R^1 is amino.
10


17. The compound of claim 15 wherein R^1 is C_1 alkyl amino (methylamino).

18. The compound of claim 7 which is selected from:


15 (a) 2,7-dihydroxy-1-methylaminopyrrolizidine:




20 (b) 2,7-dihydroxy-1-aminopyrrolizidine:




(c) 2-hydroxy-1-aminopyrrolizidine:






(d) 2-hydroxy-1-methylaminopyrrolizidine:



(e) 7-hydroxy-1-aminopyrrolizidine:




(f) 7-hydroxy-1-methylaminopyrrolizidine:

(g) 1 α -methylamino-2 β -hydroxypyrrolizidine:(h) 1 α -methylamino-7 β -hydroxypyrrolizidine:(i) 1 α -amino-2 β -hydroxypyrrolizidine;(j) 1 α -amino-7 β -hydroxypyrrolizidine;(k) 1 α -amino-2,7 β -hydroxypyrrolizidine;(l) 1 α -methylamino-2,7 β -hydroxypyrrolizidine;

(m) 2-hydroxy-1-amino-6,7-dehydropyrrolizidine.

19. The compound of claim 7 wherein R^1 is C_1 alkyl amino (methylamino) and R^2 and R^3 are oxo, having the formula:



5

20. The compound of claim 7 which is saturated and wherein R^1 , R^2 and R^3 are as shown below:

R^1	R^2	R^3
Amino	Hydrogen	Hydrogen
Amino	Hydrogen	Oxo
Amino	Hydrogen	Hydroxy
Amino	Hydrogen	Halo
Amino	Hydrogen	Alkoxy
Amino	Oxo	Hydrogen
Amino	Oxo	Oxo
Amino	Oxo	Hydroxy
Amino	Oxo	Halo
Amino	Oxo	Alkoxy
Amino	Hydroxy	Hydrogen
Amino	Hydroxy	Oxo
Amino	Hydroxy	Hydroxy
Amino	Hydroxy	Halo
Amino	Hydroxy	Alkoxy
Amino	Halo	Hydrogen
Amino	Halo	Oxo
Amino	Halo	Hydroxy
Amino	Halo	Halo
Amino	Halo	Alkoxy
Amino	Alkoxy	Hydrogen
Amino	Alkoxy	Oxo
Amino	Alkoxy	Hydroxy
Amino	Alkoxy	Halo

Amino	Alkoxy	Alkoxy
Methylamino	Hydrogen	Hydrogen
Methylamino	Hydrogen	Oxo
Methylamino	Hydrogen	Hydroxy
Methylamino	Hydrogen	Halo
Methylamino	Hydrogen	Alkoxy
Methylamino	Oxo	Hydrogen
Methylamino	Oxo	Oxo
Methylamino	Oxo	Hydroxy
Methylamino	Oxo	Halo
Methylamino	Oxo	Alkoxy
Methylamino	Hydroxy	Hydrogen
Methylamino	Hydroxy	Oxo
Methylamino	Hydroxy	Hydroxy
Methylamino	Hydroxy	Halo
Methylamino	Hydroxy	Alkoxy
Methylamino	Halo	Hydrogen
Methylamino	Halo	Oxo
Methylamino	Halo	Hydroxy
Methylamino	Halo	Halo
Methylamino	Halo	Alkoxy
Methylamino	Alkoxy	Hydrogen
Methylamino	Alkoxy	Oxo
Methylamino	Alkoxy	Hydroxy
Methylamino	Alkoxy	Halo
Methylamino	Alkoxy	Alkoxy
Alkylamino	Hydrogen	Hydrogen
Alkylamino	Hydrogen	Oxo
Alkylamino	Hydrogen	Hydroxy
Alkylamino	Hydrogen	Halo
Alkylamino	Hydrogen	Alkoxy
Alkylamino	Oxo	Hydrogen
Alkylamino	Oxo	Oxo
Alkylamino	Oxo	Hydroxy
Alkylamino	Oxo	Halo

Alkylamino	Oxo	Alkoxy
Alkylamino	Hydroxy	Hydrogen
Alkylamino	Hydroxy	Oxo
Alkylamino	Hydroxy	Hydroxy
Alkylamino	Hydroxy	Halo
Alkylamino	Hydroxy	Alkoxy
Alkylamino	Halo	Hydrogen
Alkylamino	Halo	Oxo
Alkylamino	Halo	Hydroxy
Alkylamino	Halo	Halo
Alkylamino	Halo	Alkoxy
Alkylamino	Alkoxy	Hydrogen
Alkylamino	Alkoxy	Oxo
Alkylamino	Alkoxy	Hydroxy
Alkylamino	Alkoxy	Halo
Alkylamino	Alkoxy	Alkoxy

21. The compound of claim 7 which is unsaturated and wherein R^1 , R^2 and R^3 are as shown in the table of claim 20.

5

22. The compound of claim 21 which is 1,2-dehydro-, 5,6-dehydro-, 6,7-dehydro or 7,8-dehydro.

23. The compound of any one of claims 20 to 22 wherein the alkoxy is C_1 , C_2 , C_3 , C_4 , C_5 or C_6 alkoxy.

10

24. The compound of any one of claims 20 to 23 wherein the alkylamino is C_1 , C_2 , C_3 , C_4 , C_5 or C_6 alkylamino.

15

25. The compound of any one of claims 20 to 24 wherein the halo is chloro, fluoro, iodo or bromo.

26. A method of treating or preventing a bacterial infection comprising administering to a patient in need thereof a therapeutically effective amount of the compound as defined in any one of the preceding claims.

20

27. The method of claim 26 wherein the bacterial infection comprises infection with a Gram-positive bacterium.

5 28. The method of claim 27 wherein the Gram-positive bacterium is a low G+C Gram-positive bacterium.

29. The method of claim 28 wherein the low G+C Gram-positive bacterium is a *Staphylococcus* spp. or a *Bacillus* spp..

10

30. The method of claim 29 wherein the *Staphylococcus* spp. is *S. aureus* or *S. epidermidis*).

31. The method of claim 29 wherein the *Staphylococcus* spp. is MRSA, for example
15 selected from any of C-MSRA1, C-MRSA2, C-MRSA3, C-MSRA4, Belgian MRSA, Swiss MRSA and any of the EMRSA strains.

32. The method of claim 29 wherein the *Bacillus* spp. is *Bacillus anthracis*.

20 33. Use of the compound as defined in any one of claims 1 to 25 for the manufacture of a medicament for use as an antibacterial agent.

34. A process for the manufacture of an antibacterial agent characterized in the use of the compound as defined in any one of claims 1 to 25.

25

35. The use of claim 33 or process of claim 34 wherein the antibacterial agent is for use as defined in any one of claims 26 to 32.

36. A composition comprising the compound as defined in any one of claims 1 to 25 in
30 combination with:

(f) an antimicrobial (e.g. antibacterial) agent; and/or

(g) an antiviral agent; and/or

(h) an anti-inflammatory; and/or

35 (i) an analgesic; and/or

(j) an immunostimulant.

37. A pharmaceutical kit of parts comprising the compound as defined in any one of claims 1 to 25, optionally in combination with any or all of the adjunctive therapeutic agents defined in claim 36 (a)-(e).

5 38. The kit of claim 37 further comprising instructions for use in antibacterial treatment or prophylaxis.

39. Surgical material comprising the compound as defined in any one of claims 1 to 25.

10 40. The material of claim 39 selected from:

(a) a wound dressing;

(b) an implant;

(c) a disinfectant scrub, wipe or lotion;

(d) a surgical glove;

15 (e) a catheter, probe, stent, scalpel, needle, drain, surgical clip, suture or staple.

41. A method for sterilizing or cleaning surgical material comprising application of the compound as defined in any one of claims 1 to 25.